Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial

Objective Nationwide Danish guidelines regarding rheumatoid arthritis ( RA ) patients initiating biologic treatment (i.e., biologic disease‐modifying antirheumatic drugs [ DMARD s]) are issued on an approximately annual basis. For biologics‐naive patients treated with concomitant methotrexate, mandatory medications included certolizumab pegol ( CZP ; year 2013–2014, recommended compliance 80%), abatacept ( ABA ; 2014–2015, 80%), and biosimilar...